The global sales of HBsAg testing are projected to reach USD 1,436.5 million in 2024, with expectations of growth leading to a valuation of USD 2,188.5 million by 2034. This growth represents a compound annual growth rate (CAGR) of 4.7% during the forecast period. In 2023, the revenue generated by HBsAg testing was USD 1,372.0 million.
The increasing prevalence of Hepatitis B virus (HBV) infections worldwide is a primary driver behind the rising demand for HBsAg testing. Early detection and diagnosis are critical for managing and preventing the progression of HBV-related diseases, including chronic hepatitis, cirrhosis, and liver cancer. As public awareness of hepatitis B and its health implications grows, more individuals are seeking screening and testing services.
Advancements in diagnostic technologies are further propelling market growth. Innovative testing methods, such as rapid tests and highly sensitive immunoassays, are enhancing the accuracy and speed of HBsAg detection. These technological improvements are expected to lead to greater adoption rates among healthcare providers and patients alike.
Additionally, government initiatives and public health campaigns aimed at increasing hepatitis B vaccination and screening rates are likely to contribute to market expansion. The World Health Organization (WHO) emphasizes the importance of timely diagnosis in controlling the spread of HBV, which is anticipated to increase demand for HBsAg testing in various healthcare settings.
The rapid growth of the diagnostic technologies is driving the growth of the HBsAg testing market. RDTs have greatly increased the speed and convenience of HBsAg testing. Such tests are designed for results within minutes and, therefore, are very suitable in a point-of-care setup where quick diagnosis is needed.
Advancements in automated immunoassays have increased the precision and efficiency of the process of testing HBsAg. which include integrated platforms developed by leading firms such as Thermo Fisher Scientific and BD Biosciences. The sample processing, analysis, and result reporting in these platforms have been automatically integrated into a continuous workflow process that smoothes the course of testing, be it in research or clinical applications.
This continuous innovation in the technologies makes diagnosis among patients more precise, accessible, and expands the screening programs. All this contributes to the finding of hepatitis B infection early and managing it. The rise in prevalence of these tests as mainstream tests will probably increase the HBsAg testing market significantly, since it responds to acute needs in healthcare internationally and facilitates the fight against the disease.
Prevalence is rather different across regions. The highest prevalence is in the African and Western Pacific regions, where 6.1% and 6.2% of adults have the infection, respectively. In this respect, there is a great need for regional public health intervention and diagnostic activity. Chronic infection due to hepatitis B is associated with significant long-term complication risks and increased mortality.
It is estimated that a very big percentage, 80-90% of newborns who get infected with hepatitis B within the first year of life, develop chronic infections; this calls for early detection and interventions. Due to increasing urbanization and alteration in lifestyle, new cases of hepatitis B will definitely rise, which in turn shifts the global health dynamics.
The growing prevalence creates more demand for advanced diagnostic tools and comprehensive screening programs. This, in turn, fosters a better market position for hepatitis B diagnostic test manufacturers. Furthermore, the increasing prevalence, coupled with an emergent need for detection and intervention strategies, provides a significant opportunity for innovation and growth in the hepatitis B diagnostics market.
Competitive Landscape
The HBsAg testing market is highly fragmented, with a large number of manufacturers involved in the development and refining of new advanced products to cater to various customer demands. Market growth may be endorsed by demand for advanced diagnostic solutions, which, in turn, has accelerated international expansion and strategic acquisitions amongst leading players.
Recent Industry Developments in HBsAg Testing Market
- On April 15, 2024, Thermo Fisher Scientific Inc. introduced the TaqMan™ HBsAg Assay, an advanced diagnostic tool designed to improve the sensitivity and specificity of hepatitis B testing. This new assay aims to provide more accurate results, catering to the growing demand for precise diagnostics in clinical settings.
- In February 2024, Danaher Corporation launched its CLIA HBsAg Detection Kit, which integrates the latest advancements in chemiluminescent immunoassay technology. This kit is expected to enhance testing efficiency and throughput, addressing the needs of both high-volume laboratories and smaller diagnostic centers.
- On March 10, 2024, BD Biosciences announced a strategic collaboration with GSK Bio, a global biopharmaceutical leader, to develop and deploy a novel HBsAg testing platform. This partnership aims to combine BD’s expertise in diagnostic technology with GSK’s biopharmaceutical insights to improve the early detection and management of hepatitis B.
Full Report Revealed
Key Players of HBsAg Testing Industry
- CTK Biotech Inc.
- Biopanda Reagents Ltd.
- Avecon Healthcare Pvt Ltd.
- Abbott
- Bio-Rad Laboratories Inc.
- Siemens Healthineers
- QIAGEN
- F. Hoffmann-La Roche AG.
Key Segments of HBsAg Testing Industry
By Kits:
In terms of Kits, the industry is divided into cassettes/cards and strips
By Sample:
In terms of sample, the industry is divided into serum, plasma and whole blood
By End User:
In terms of end user, the industry is segregated into hospitals, clinics, diagnostic centres, home care and others
By Region:
Key countries of North America, Latin America, Europe, East Asia, South Asia & Pacific, Middle East and Africa (MEA) have been covered in the report.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
